Ottawa Nutritional Guidelines for Nausea and Vomiting

Effect of Implementing Ottawa Nutritional Guidelines on the Course of Nausea and Vomiting During Pregnancy (A Randomized Control Trial)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05370170

Enrollment

Registered

2022-05-11

Start date

2021-01-01

Completion date

2021-09-30

Last updated

2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea Gravidarum

Brief summary

Effect of Implementing Ottawa Nutritional Guidelines on the Course of Nausea and Vomiting During Pregnancy (A Randomized Control Trial)

Detailed description

Studying the Effect of Implementing Ottawa Nutritional Guidelines on the Course of Nausea and Vomiting During Pregnancy (A Randomized Control Trial) using no pharmacological agents and life style modification in addition to acupressure to treat nausea and vomiting of pregnancy

Interventions

BEHAVIORALAcupressure and nutritional advices

Teaching using booklets and application of acupressure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

22 Years to 35 Years

Healthy volunteers

Inclusion criteria

1. primigravida 2. gestational age of 7-13 weeks 3. singleton pregnancy 4. having a score of 7-12 on the (PUQE 24) 5. can read and write 6. having phone number 7. not receiving medications for reducing NVP, except for vitamin B6 8. wanted pregnancy.

Exclusion criteria

1. subject's unwillingness to continue the study 2. occurrence of obstetric complications during the study 3. hyper-emesis gravidarum 4. having physical or mental disorders 5. having oral/speech impairments 6. having assisted reproductive techniques for the present pregnancy 7. having two consecutive miscarriages before the current pregnancy 8. old primigravida 9. narcotic use or alcohol drinking 10. and subjects who will show signs and symptoms of hyperemesis gravidarum during the study will be dropped out and referred to medical care.

Design outcomes

Primary

Measure	Time frame	Description
control nausea and vomiting	3 weeks	control the frequency and severity of nausea and vomiting and measure it by using Pregnancy Unique Quantification of Emesis

Secondary

Measure	Time frame	Description
maintain normal body weight and prevent hospitalization	3 weeks	Monitor mother weight by calipered weight scale to monitor weight loss related to nausea and vomiting

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026